Company Overview and News

 
ThromboGenics Business Update - H1 2018

2018-09-06 globenewswire
Following shareholders' approval at an EGM held on September 3, 2018, and effective as of September 10, 2018, ThromboGenics NV is changing its corporate name to Oxurion NV. The new name Oxurion is designed to better reflect the company's ambition to deliver best in class therapies for back of the eye disorders, following recent progress made with the company's innovative diabetic eye disease pipeline.
THR TBGNF

 
ThromboGenics becomes "Oxurion"

2018-09-03 globenewswire
Shareholders approve new name which better reflects the Company's ambition to deliver best in class therapies for back of the eye disorders
THR TBGNF

 
ThromboGenics Reports Day 150 Topline Data from its Phase 1/2 Clinical Study evaluating THR-317 (anti-PlGF) for the Treatment of Diabetic Macular Edema (DME)

2018-07-19 globenewswire
Study results confirm safety and tolerability of THR-317 for intra-ocular use, and show improvement in visual acuity for up to 90 days after last injection
THR TBGNF

 
ThromboGenics Plans Name Change to "Oxurion"

2018-06-27 globenewswire
To better reflect Company's activities and ambition to deliver best in class therapies for back of the eye disorders
THR TBGNF

 
ThromboGenics Partners with Prevent Blindness at 2018 Focus on Eye Health National Summit in Washington DC

2018-06-21 globenewswire
Leuven, Belgium, 21 June 2018 - ThromboGenics NV (Euronext Brussels: THR), a biopharma company focused on developing novel treatments for back of the eye diseases with an innovative pipeline in diabetic eye disease, announces its participation and support of the seventh annual Prevent Blindness Focus on Eye Health National Summit which takes place on July 18, 2018, at the National Press Club in Washington, DC.
THR TBGNF

 
ThromboGenics Enrolls First Patient in Phase 1 Clinical Study Evaluating THR-149, a plasma kallikrein inhibitor, for treatment of Diabetic Macular Edema (DME)

2018-05-25 globenewswire
Leuven, Belgium, 25 May 2018 - ThromboGenics NV (Euronext Brussels: THR), a biotechnology company developing novel medicines for diabetic eye disease, announces that it has successfully enrolled the first patient in a Phase 1 open-label, multicenter, dose escalation study evaluating the safety of THR-149 in the treatment of DME (NCT03511898).
THR TBGNF

 
ThromboGenics to present a preclinical overview of its two most advanced diabetic eye disease clinical candidates, THR-317 and THR-149, at EASDec 2018

2018-05-23 globenewswire
Leuven, Belgium, 23 May 2018 - ThromboGenics NV (Euronext Brussels: THR), a biotechnology company developing novel medicines for diabetic eye disease, announces that its CSO Jean Feyen, PhD, and Senior Scientist Tine Van Bergen, PhD, will present at the European Association for the Study of Diabetes Eye Complications Study Group (EASDec) Annual Meeting 2018, which takes place from the 24-26 May in Belfast, Northern Ireland.
THR TBGNF

 
ThromboGenics Business Update - Q1 2018

2018-05-09 globenewswire
Positive Initial Topline Data from Phase 1/ 2a Clinical Study evaluating THR-317, anti-PlGF, for the Treatment of Diabetic Macular Edema (DME)
THR TBGNF

 
ThromboGenics Initiates Phase 2 Clinical Study Evaluating anti-PlGF (THR-317) in combination with anti-VEGF (ranibizumab) for treatment of Diabetic Macular Edema (DME)

2018-04-27 globenewswire
Leuven, Belgium, April 27 2018 - ThromboGenics NV (Euronext Brussels: THR), a biotechnology company developing novel medicines for diabetic eye disease, announces that it has successfully enrolled the first patient in a Phase 2 active-controlled, masked, multicenter study to evaluate the efficacy and safety of THR-317 administered in combination with ranibizumab (Lucentis®, Novartis), for the treatment of DME (NCT03499223).
THR TBGNF

 
ThromboGenics Reports Initial Data from its Clinical Study evaluating THR-317, an anti-PlGF, for the Treatment of Diabetic Macular Edema (DME)

2018-04-04 globenewswire
30% of anti-VEGF treatment naïve patients had a 3 line or more (> or equal to 15 letters) gain in Best Corrected Visual Acuity (BVCA) after 3 monthly injections with THR-317 (8mg)
THR TBGNF

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Silicon Investor Message Boards

This table lists all message boards related to EBR:THR / THROMBOGENICS on message board site Silicon Investor.

The Exxon Free Environmental Thread The Exxon Free Environmental Thread The Exxon Free Environmental Thread Golf! A thread for the hopelessly addicted! Golf! A thread for the hopelessly addicted! Golf! A thread for the hopelessly addicted!
Qualcomm Moderated Thread - please read rules before posting Qualcomm Moderated Thread - please read rules before posting Qualcomm Moderated Thread - please read rules before posting Foreign Policy Discussion Thread Foreign Policy Discussion Thread Foreign Policy Discussion Thread
The New Qualcomm - write what you like thread. The New Qualcomm - write what you like thread. The New Qualcomm - write what you like thread. Stock Watcheru0027s Thread / Pix of the Week (POW) Stock Watcheru0027s Thread / Pix of the Week (POW) Stock Watcheru0027s Thread / Pix of the Week (POW)
Research Frontiers Lonely Hearts Club Thread. Research Frontiers Lonely Hearts Club Thread. Research Frontiers Lonely Hearts Club Thread. The Environmentalist Thread The Environmentalist Thread The Environmentalist Thread
Applied Materials No-Politics Thread (AMAT) Applied Materials No-Politics Thread (AMAT) Applied Materials No-Politics Thread (AMAT) TradeStation - Why No thread for this mega product TradeStation - Why No thread for this mega product TradeStation - Why No thread for this mega product